


Dabur India

 Relative to sector: **Neutral**

 Lead Analyst: **Hemant B Patel**
 Email: hemantp@enam.com
 Tel: 9122 6754 7617

 Associate: **Akhil Kejriwal**
 Email: akhil@enam.com
 Tel: 9122 6754 7629

Relative Performance



Source: Bloomberg, ENAM Research

Stock data

 No. of shares : 863mn
 Market cap : Rs 81bn
 52 week high/low : Rs 118/ Rs 71
 Avg. daily vol. (6mth) : 1.4mn shares
 Bloomberg code : DABUR IN
 Reuters code : DABU.BO

Shareholding (%) Mar-07 QoQ chg

Shareholder	Mar-07 (%)	QoQ chg (%)
Promoters	73.8	(0.2)
FII's	10.5	0.6
MFs / UTI	0.5	(4.0)
Banks / FIs	5.8	3.1
Others	9.4	0.4

IMPRESSIVE UNDERLYING GROWTH

Dabur India (Dabur) reported consolidated revenues of Rs 5.8bn (↑20.1%), EBIDTA of Rs 881mn (↑12%) and Adj. PAT of Rs 769mn (↑23%) in Q4FY07, all of which were inline with our expectations. Although inflationary cost pressures contracted EBITDA margins by 100bps to 15.3%, higher other income and lower tax provisioning propped up Adj. PAT margins by 28bps to 13.3 in Q4FY07.

Key Highlights –FY07

- **Category analysis:** Revenue growth of 20% YoY was driven by growth in CCD (↑16%), IBD (↑29%) & the foods division (↑26%). Key CCD segments such as shampoo, oral care and health supplements managed to outperform category growth.
- **Well-managed cost pressures:** Rise in material cost (↑95bps) was offset by prudent cost management pertaining to employees (↓17bps), A&P spend (↓22bps) and other expenses (↓91bps), resulting in a 35bps increase in EBITDA margin to 15.7% in FY07.
- **Price increase:** Dabur took a 4-5% price increase across categories in FY07 and could see similar increases going forward. However the management continues to focus on volume growth rather than price increases that are largely cost led.
- **Retail venture:** The Company intends to set up ~350 stores in the health and beauty format by 2012 with a revenue target of Rs 17bn. The first store is likely to be launched in Q4FY08.
- **Earnings outlook:** Against an earnings growth of 36% CAGR over the last 5 years, we believe earnings growth will now moderate to 21% CAGR over the next 2 years. Dabur's unique positioning with a differentiated product portfolio and presence in high categories, supports high revenue visibility.

While we have not factored in the financial forecast for the retail venture, we believe the potential for losses from this venture looms over near term earnings. With a strong focus on volume driven revenue growth, we believe that the current valuations adequately factor in the growth and cost inflation concerns. At CMP (Rs 94), the stock trades at 24x FY08E and 20x FY09E earnings. We are upgrading the stock to sector **Neutral**.

Financial summary (Consolidated)

Y/E Mar	Net Sales (Rs mn)	Adj. PAT (Rs mn)	Consensus EPS* (Rs.)	EPS* (Rs.)	Change YoY (%)	P/E (x)	RoE (%)	RoCE (%)	EV/EBIDTA (x)	DPS (Rs.)
2006	18,659	2,246	-	3.9	(27)	21.1	53.3	49.3	16.6	2.5
2007	21,999	2,830	-	3.3	(16)	29.0	59.3	55.1	22.8	1.8
2008E	25,509	3,416	3.9	4.0	21	23.8	64.3	60.9	19.2	2.5
2009E	28,992	4,137	4.5	4.8	21	19.7	65.0	69.3	16.7	3.0


Source: *Consensus broker estimates, Company, ENAM estimates *Note: Bonus shares of 1:1 and 1:2 were issued in Jan-06 & Jan-07 respectively.

Results update (Consolidated)


(Rs mn)	Quarter ended					12 months ended		
	Mar-07	Mar-06	% Chg	Dec-06	% Chg	Mar-08E	Mar-07	% Chg
Net Sales	5,765	4,799	20.1	6,176	(6.7)	25,509	21,999	16.0
EBIDTA	881	783	12.5	1,004	(12.2)	4,183	3,497	19.6
Other income	71	22	223.7	33	116.8	210	259	(18.9)
PBIDT	952	805	18.2	1,037	(8.2)	4,393	3,756	17.0
Depreciation	90	69	30.9	115	(21.9)	303	400	(24.1)
Interest	28	24	15.9	31	(9.2)	164	154	5.9
PBT	834	713	17.1	891	(6.3)	3,927	3,202	22.6
Tax	54	80	(31.9)	115	(52.7)	510	381	34.0
Minority Interest	11	6	82.0	(17)	-	-	(9)	-
Adjusted PAT	769	627	22.7	793	(3.0)	3,416	2,830	20.7
Extra ordinary income/ (exp.)	-	(127)	-	-	-	-	-	-
Reported PAT	769	500	53.8	793	(3.0)	3,416	2,830	20.7
No. of shares (mn)	863	573	-	574	-	863	863	-
EBIDTA margins (%)	15.3	16.3	-	16.3	-	16.4	15.9	-
PBIDT margins (%)	16.5	16.8	-	16.8	-	17.2	17.1	-
EPS - annualized (Rs.)	3.6	4.4	(18.5)	5.5	(35.5)	4.0	3.3	20.7

Source: Company, ENAM estimates

Revenue & EBITDA trend (consolidated)



Sales Mix Trend



Source: Company, ENAM Research

Category Analysis –FY07

Category	% of sales	Growth YoY	Remarks
Consumer Care Div.	69	16	All major categories in the CCD division grew in strong double digits to deliver a robust growth of 15.6% YoY in FY07.
- Hair Care	22	16	Hair oils grew by 13% YoY backed by Amla Hair oil (↑11.4%), Anmol coconut oil (↑44.4%) and Anmol mustard (↑28.3%). The shampoo portfolio grew by 31%, outperforming the category growth of 12% for they year.
- Oral Care	15	17	Oral care grew at 23.7% in volume terms as against category growth(market) of 15.3%. The toothpaste segment grew by 27.9% YoY. Babool again led the pack with a 49.3% YoY growth. Dabur's share in toothpaste category increased by 130 bps to 10.4%. Toothpowder also grew by 7% in FY07 against negative growth last year.
- Health Supplements	15	19	All three major brands in the category once again recorded strong double-digit growth with Chyawanprash (↑20%), Glucose (↑27%) and Honey (↑15%). Chyawanprash's sugar free variant is currently being test marketed. Market share for Chyawanprash was maintained at 58%.
- Digestives & Candies	7	6	Hajmola brands continued the growth trend with tablets (↑10.5%) & candy (↑18.4%). Lemon flavor variant was launched in Hajmola tablets.
- Baby & Skin Care	5	(1)	Growth in Gulabari (↑2%) remained flat once again; Lal Tail was up by 11% YoY. A third Vatika soap variant was launched.
- Home Care	5	35	Odonil air freshner grew by 28.2% YoY. Odomos mosquito repellent brand grew by 71% in FY07. Odomos coil launched in Q1FY07 expanded its reach.
Consumer Health Div.	7	9	Growth in the CHD was impacted as the business is being consolidated due to the acquisition in FY06. Distribution systems were also rationalized. We believe this is one time & have estimated a 10% YoY growth in CHD for FY08E.
Foods	11	26	Foods category posted robust growth and crossed the Rs 2bn sales mark. 'Real' fruit juices posted a growth of 28% YoY with new launches in the Activ range & Real portfolio. 3 variants were launched under Real Twist.
International Business	13	29	GCC and Egypt markets grew by a strong 29% and 59% respectively in FY07. Exports have started to new markets in the Middle East & North Africa. Sales in Pakistan once again doubled to reach Rs 200mn.
Total sales	100	18	We estimate the revenue growth for the consolidated entity at 16% and 14%, for FY08E and FY09E respectively.

Source: Company Note: the above forecast does not include retail venture.

Dabur's retail foray

Dabur unveiled its retail roadmap in Q4FY07 with a bold plan of 350 stores on the health & beauty (H&B) format with target revenue of Rs 17bn by 2012. Dabur will infuse Rs 1.4bn as equity into the subsidiary with additional debt after a couple of years, to establish its presence in the retail market in India. The retail venture will operate through a wholly-owned subsidiary, H&B Stores Limited under a separate brand name. Dabur plans to cater primarily to the upper-class urban consumer and plans to establish stores ranging from 1,500 sq ft to 6,000 sq ft in size, with initial rollouts in Metros and Tier-I cities. The first such store is likely to be launched in Q4FY08. The retail team is likely to be in place by Q1FY08.

Retail Vision 2012
Premium H&B
Revenue – Rs 17 bn
Stores – 350 nos.

The product mix will cover pharmacy and OTC health, personal care, baby care, cosmetics, and general merchandise. While the range of categories is wide, the

focus of the proposition will be health and beauty. The stores will maintain a balance between own/private labels and Dabur's own brands.

In terms of performance, Dabur expects to start generating profits by the fourth year of operations with revenue exceeding Rs 10bn. According to the management the total retail market size in India is estimated to be USD 258bn, of which H&B retail accounts for USD 34bn (13%). This presents a huge opportunity, as organized retail penetration of the H&B market is very low at 2%.

The management expects the retail venture to generate profits in FY2011 with margins similar to other international players in the H&B retail space. Considering the nascent stage of the venture, we believe more clarity will emerge in terms of the planned rollout and investments, once the retail team is in place. We have not included the retail venture into our financial forecast for FY08E & FY09E.

This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Nothing in this document should be construed as investment or financial advice, and nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. The intent of this document is not in recommendatory nature

Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors

Enam Securities Private Limited has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval

Enam securities Private Limited, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document

This report has been prepared on the basis of information, which is already available in publicly accessible media or developed through analysis of ENAM Securities Private Limited. The views expressed are those of analyst and the Company may or may not subscribe to all the views expressed therein

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions

Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

Copyright in this document vests exclusively with ENAM Securities Private Limited.